Catalent (NYSE:CTLT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a research report sent to investors on Saturday. The firm issued a hold rating on the stock.

Other research analysts have also issued research reports about the company. Robert W. Baird reiterated a “neutral” rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Eight analysts have rated the stock with a hold rating, According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $63.40.

Catalent Stock Performance

Shares of CTLT stock opened at $63.48 on Friday. The business’s fifty day moving average price is $61.37 and its 200 day moving average price is $59.96. The firm has a market capitalization of $11.52 billion, a PE ratio of -28.09, a P/E/G ratio of 2.70 and a beta of 1.15. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. Catalent has a 1-year low of $41.15 and a 1-year high of $63.50.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the previous year, the firm posted ($0.10) EPS. The business’s revenue was up 4.2% on a year-over-year basis. As a group, sell-side analysts forecast that Catalent will post 0.78 EPS for the current fiscal year.

Insider Activity at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. This represents a 20.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.31% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Catalent

Several large investors have recently made changes to their positions in CTLT. Brooklyn Investment Group bought a new stake in Catalent in the third quarter worth approximately $31,000. Sentry Investment Management LLC acquired a new position in Catalent during the third quarter worth $53,000. Longfellow Investment Management Co. LLC raised its holdings in Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after buying an additional 305 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. lifted its position in shares of Catalent by 57.5% in the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock worth $72,000 after buying an additional 431 shares during the last quarter. Finally, Intact Investment Management Inc. bought a new stake in shares of Catalent during the 3rd quarter worth about $73,000.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.